120 related articles for article (PubMed ID: 38843774)
21. Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest.
Huang Y; Huang S; Wei W; Wu Y; Jia L; Du Y; Luo P; Pan W
J Inorg Biochem; 2024 Jan; 250():112421. PubMed ID: 37922609
[TBL] [Abstract][Full Text] [Related]
22. Thiabendazole-based Rh(III) and Ir(III) biscyclometallated complexes with mitochondria-targeted anticancer activity and metal-sensitive photodynamic activity.
Pérez-Arnaiz C; Acuña MI; Busto N; Echevarría I; Martínez-Alonso M; Espino G; García B; Domínguez F
Eur J Med Chem; 2018 Sep; 157():279-293. PubMed ID: 30099251
[TBL] [Abstract][Full Text] [Related]
23. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
24. Valproic Acid-Functionalized Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.
Ye RR; Cao JJ; Tan CP; Ji LN; Mao ZW
Chemistry; 2017 Oct; 23(60):15166-15176. PubMed ID: 28833658
[TBL] [Abstract][Full Text] [Related]
25. Anticancer Activity of Half-Sandwich Ru, Rh and Ir Complexes with Chrysin Derived Ligands: Strong Effect of the Side Chain in the Ligand and Influence of the Metal.
Rubio AR; González R; Busto N; Vaquero M; Iglesias AL; Jalón FA; Espino G; Rodríguez AM; García B; Manzano BR
Pharmaceutics; 2021 Sep; 13(10):. PubMed ID: 34683834
[TBL] [Abstract][Full Text] [Related]
26. Anticancer application of ferrocene appended configuration-regulated half-sandwich iridium(III) pyridine complexes.
Wang Z; Lv Z; Liu X; Wu Y; Chang J; Dong R; Li C; Yuan XA; Liu Z
J Inorg Biochem; 2022 Dec; 237():112010. PubMed ID: 36152469
[TBL] [Abstract][Full Text] [Related]
27. The anticancer application of half-sandwich iridium(III) ferrocene-thiosemicarbazide Schiff base complexes.
Liu X; Lv A; Zhang P; Chang J; Dong R; Liu M; Liu J; Huang X; Yuan XA; Liu Z
Dalton Trans; 2024 Jan; 53(2):552-563. PubMed ID: 38054240
[TBL] [Abstract][Full Text] [Related]
28. Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.
Hearn JM; Hughes GM; Romero-Canelón I; Munro AF; Rubio-Ruiz B; Liu Z; Carragher NO; Sadler PJ
Metallomics; 2018 Jan; 10(1):93-107. PubMed ID: 29131211
[TBL] [Abstract][Full Text] [Related]
29. Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.
Ouyang M; Zeng L; Huang H; Jin C; Liu J; Chen Y; Ji L; Chao H
Dalton Trans; 2017 May; 46(20):6734-6744. PubMed ID: 28488721
[TBL] [Abstract][Full Text] [Related]
30. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
31. "Half-sandwich" Schiff-base Ir(III) complexes as anticancer agents.
Mou ZD; Deng N; Zhang F; Zhang J; Cen J; Zhang X
Eur J Med Chem; 2017 Sep; 138():72-82. PubMed ID: 28646657
[TBL] [Abstract][Full Text] [Related]
32. Group 9 organometallic compounds for therapeutic and bioanalytical applications.
Ma DL; Chan DS; Leung CH
Acc Chem Res; 2014 Dec; 47(12):3614-31. PubMed ID: 25369127
[TBL] [Abstract][Full Text] [Related]
33. Mitochondria-targeted cyclometalated iridium (III) complexes: Dual induction of A549 cells apoptosis and autophagy.
Chen L; Tang H; Chen W; Wang J; Zhang S; Gao J; Chen Y; Zhu X; Huang Z; Chen J
J Inorg Biochem; 2023 Dec; 249():112397. PubMed ID: 37844533
[TBL] [Abstract][Full Text] [Related]
34. Reactive Oxygen Species Production Is Responsible for Antineoplastic Activity of Osmium, Ruthenium, Iridium and Rhodium Half-Sandwich Type Complexes with Bidentate Glycosyl Heterocyclic Ligands in Various Cancer Cell Models.
Kacsir I; Sipos A; Bényei A; Janka E; Buglyó P; Somsák L; Bai P; Bokor É
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054999
[TBL] [Abstract][Full Text] [Related]
35. Half-sandwich iridium N-heterocyclic carbene anticancer complexes.
Wang C; Liu J; Tian Z; Tian M; Tian L; Zhao W; Liu Z
Dalton Trans; 2017 May; 46(21):6870-6883. PubMed ID: 28405646
[TBL] [Abstract][Full Text] [Related]
36. Significant effects of counteranions on the anticancer activity of iridium(iii) complexes.
Zhang H; Guo L; Tian Z; Tian M; Zhang S; Xu Z; Gong P; Zheng X; Zhao J; Liu Z
Chem Commun (Camb); 2018 Apr; 54(35):4421-4424. PubMed ID: 29648559
[TBL] [Abstract][Full Text] [Related]
37. Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.
Hearn JM; Romero-Canelón I; Qamar B; Liu Z; Hands-Portman I; Sadler PJ
ACS Chem Biol; 2013; 8(6):1335-43. PubMed ID: 23618382
[TBL] [Abstract][Full Text] [Related]
38. Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents.
Wu Y; Liu J; Shao M; Zhang P; Song S; Yang G; Liu X; Liu Z
J Inorg Biochem; 2022 Aug; 233():111855. PubMed ID: 35576884
[TBL] [Abstract][Full Text] [Related]
39. In Vitro and In Vivo Antitumor Assay of Mitochondrially Targeted Fluorescent Half-Sandwich Iridium(III) Pyridine Complexes.
Wang L; Liu X; Wu Y; He X; Guo X; Gao W; Tan L; Yuan XA; Liu J; Liu Z
Inorg Chem; 2023 Feb; 62(8):3395-3408. PubMed ID: 36763897
[TBL] [Abstract][Full Text] [Related]
40. Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents.
Song XD; Kong X; He SF; Chen JX; Sun J; Chen BB; Zhao JW; Mao ZW
Eur J Med Chem; 2017 Sep; 138():246-254. PubMed ID: 28668477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
